Marinus Pharmaceuticals to Provide Business Update and Report Second Quarter 2023 Financial Results on August 10, 2023
27 Julho 2023 - 8:01AM
Business Wire
Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical
company dedicated to the development of innovative therapeutics to
treat seizure disorders, today announced that it plans to release
financial results for the second quarter ended June 30, 2023 on
August 10, 2023. The Company will host a conference call at 8:30
a.m. Eastern Time on August 10, 2023.
Participants may access the conference call via webcast on the
Investors and Media page of Marinus’ website at
ir.marinuspharma.com/events-and-presentations. An archived version
of the call will be available approximately two hours after the
completion of the event on the website.
About Marinus Pharmaceuticals
Marinus is a commercial stage pharmaceutical company dedicated
to the development of innovative therapeutics for seizure
disorders. The Company’s commercial product, ZTALMY® (ganaxolone)
oral suspension CV, has been approved by the U.S. FDA for the
treatment of seizures associated with CDKL5 deficiency disorder in
patients two years of age and older. The potential of ganaxolone is
also being studied in other rare seizure disorders, including in
Phase 3 trials in tuberous sclerosis complex and refractory status
epilepticus. Ganaxolone is a neuroactive steroid GABAA receptor
modulator that acts on a well-characterized target in the brain
known to have anti-seizure effects. It is being developed in IV and
oral formulations to maximize therapeutic reach for adult and
pediatric patients in acute and chronic care settings. For more
information visit www.marinuspharma.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230727626834/en/
Company Molly Cameron Director, Corporate Communications
& Investor Relations Marinus Pharmaceuticals, Inc.
mcameron@marinuspharma.com
Marinus Pharmaceuticals (NASDAQ:MRNS)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Marinus Pharmaceuticals (NASDAQ:MRNS)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024